|
|
Post by brotherm1 on Mar 31, 2016 21:38:13 GMT -5
A Sean Cunningham is the managing director for GTCR
|
|
|
|
Post by cathode on Mar 31, 2016 21:56:00 GMT -5
On the mNKD Yahoo mssg board tonight it appears a couple of posters have connected dots and very possibly found a strong connection between Receptor and GTCR. GTCR has a few billion $ and is in partnership with an ex senior executive from Abbot labs and was Presiident in charge of the diabetes section for Abbot (if I got this correct). Their new company TerSera(?) will be buying and working with fda approved material or late stage development drugs/devices (again if I remember the posts correctly). The post on the Yahoo mssg board thread is titled Another Receptor Theory From YMB poster madog365 on March 31: Here is the press release mentioned. www.gtcr.com/gtcr-announces-third-partnership-with-ed-fiorentino-to-form-tersera-therapeutics/TerSera doesn't seem to fit what Matt has said about RLS to date, namely that it is an existing company that has "been around for a while". I don't know if I am buying this latest theory. |
|
|
|
Post by brotherm1 on Mar 31, 2016 22:15:09 GMT -5
|
|
|
|
Post by brotherm1 on Mar 31, 2016 22:18:13 GMT -5
Sorry Cathode I misread your post. Albeit TerSera is new perhaps RLS is still related to TerSera?
|
|
|
|
Post by madog365 on Apr 1, 2016 10:08:09 GMT -5
Let me further elaborate since the the YMB post has been mysteriously deleted even though it broke no rules.
Tersera is a new company but GTCR (the financing behind them) is a very well respected private equity shop with over 10 billion in assets. They've done this type of thing numerous times in partnership with Ed Fiorentino, each time with a successful exit.
TerSera is the third partnership between GTCR and Ed Fiorentino and another example of the GTCR Leaders StrategyTM. Previously, Mr. Fiorentino was Chairman and Chief Executive Officer of Crealta Pharmaceuticals LLC, a GTCR-funded specialty pharmaceutical company which was acquired in January 2016 by Horizon Pharma plc. Through organic growth initiatives and four transactions, Crealta built a unique specialty pharmaceutical company focused on niche therapeutic markets within rheumatology and the central nervous system
Prior to his role at Crealta, Mr. Fiorentino was the Chief Executive Officer of Actient Pharmaceuticals LLC, a specialty pharmaceutical company established in partnership with GTCR. Actient built a growing and diversified portfolio of commercial products and pipeline programs focused on the treatment of urological conditions before ultimately being acquired by Auxilium Pharmaceuticals.
It does fit Matt's statement that there are some well respected/established investors behind receptor with proven results.
Also let me add on
Jagla is the trademark attorney on record for Receptor - that is a fact. The rest of my post is all speculation.
She worked 15 years at Abbott Labs of which all of those years Fiorentino also worked there as well as an executive. I don't know how much they overlapped day to day but the connection is definitely there. It's not too far-fetched to assume that he would go to a trademark attorney he knows for legal advice / assistance when setting up Receptor.
I think when news of Receptor came out everyone was looking at the name Gregory Wesner to connect dots when he may just have been assisting Jagla as they work at the same law firm.
|
|
|
|
Post by navpoon on Apr 1, 2016 10:39:15 GMT -5
A friend of mine that works at Novartis said that someone from Regeneron board has joined board of Receptor Life. Can anyone confirm this? If that is so Receptor Life may be a dual entity Google/Sny?? But with how the relationship fell apart with MNkD and SNY I can't see this being true.
any sleuths out there can dig up this lead?
|
|
|
|
Post by bthomas55ep on Apr 1, 2016 12:02:00 GMT -5
A friend of mine that works at Novartis said that someone from Regeneron board has joined board of Receptor Life. Can anyone confirm this? If that is so Receptor Life may be a dual entity Google/Sny?? But with how the relationship fell apart with MNkD and SNY I can't see this being true. any sleuths out there can dig up this lead? Just a comment - The association of Google/Sny doesn't have to be made in RLS references. Google/Sny are partnering on global diabetes. RLS is not attempting to address diabetes, therefore, Sny should be in no way involved. Could Google be involved way back behind the scenes as another potential letter in their Alphabet? Perhaps, but if RLS is medical cannabis, then I believe the proof of concept would need to be well down the track before it would come out. Is it possible that someone from Sanofi told someone from Google that the Technosphere technology is legit and they decided to fund an RLS proof of concept on their drug....? Maybe...., but who knows. |
|
|
|
Post by peppy on Apr 1, 2016 12:55:33 GMT -5
On the mNKD Yahoo mssg board tonight it appears a couple of posters have connected dots and very possibly found a strong connection between Receptor and GTCR. GTCR has a few billion $ and is in partnership with an ex senior executive from Abbot labs and was Presiident in charge of the diabetes section for Abbot (if I got this correct). Their new company TerSera(?) will be buying and working with fda approved material or late stage development drugs/devices (again if I remember the posts correctly). The post on the Yahoo mssg board thread is titled Another Receptor Theory From YMB poster madog365 on March 31: Here is the press release mentioned. www.gtcr.com/gtcr-announces-third-partnership-with-ed-fiorentino-to-form-tersera-therapeutics/TerSera doesn't seem to fit what Matt has said about RLS to date, namely that it is an existing company that has "been around for a while". I don't know if I am buying this latest theory. cathode: of all the researchers and postings on this thread, I trust your take, at these moments. What do you think? What is your take?
And all, what is the take?
|
|
|
|
Post by dreamboatcruise on Apr 1, 2016 13:02:45 GMT -5
cathode: of all the researchers and postings on this thread, I trust your take, at these moments. What do you think? What is your take?
And all, what is the take?
My take is that it is unlikely of importance to MNKD who the backers of RLS are. I'll take Matt at his word that they are legit and have funding, as there is no reason to believe they are not. Whether and when we get milestone payments will not change based on who the money is behind RLS. |
|
|
|
Post by biffn on Apr 1, 2016 13:26:20 GMT -5
A friend of mine that works at Novartis said that someone from Regeneron board has joined board of Receptor Life. Can anyone confirm this? If that is so Receptor Life may be a dual entity Google/Sny?? But with how the relationship fell apart with MNkD and SNY I can't see this being true. any sleuths out there can dig up this lead? Could be the Google is running the show. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 1, 2016 13:43:57 GMT -5
cathode: of all the researchers and postings on this thread, I trust your take, at these moments. What do you think? What is your take?
And all, what is the take?
My take is that it is unlikely of importance to MNKD who the backers of RLS are. I'll take Matt at his word that they are legit and have funding, as there is no reason to believe they are not. Whether and when we get milestone payments will not change based on who the money is behind RLS. Matt did say they were respected members of the Seattle community. Obvious names that come to mind: Bill Gates, Paul Allen, Jeff Bezos, Howard Schultz, Steve Ballmer. Here is another one - complete guess on my part Nathan Myhrvold His Wiki page says he studied at UCLA so what the hell, with all the other unsubstantiated theories, I thought I would throw him into the hat. en.wikipedia.org/wiki/Nathan_Myhrvold"Myhrvold was born in Seattle, Washington. He attended Mirman School,[4] and began college at age 14.[5] He studied mathematics, geophysics, and space physics at UCLA (BSc, Masters). He's a multi-billionaire and it known for his collection of patents. www.nathanmyhrvold.com |
|
|
|
Post by peppy on Apr 1, 2016 13:52:44 GMT -5
cathode: of all the researchers and postings on this thread, I trust your take, at these moments. What do you think? What is your take?
And all, what is the take?
My take is that it is unlikely of importance to MNKD who the backers of RLS are. I'll take Matt at his word that they are legit and have funding, as there is no reason to believe they are not. Whether and when we get milestone payments will not change based on who the money is behind RLS. My take: from the thread; - MNKD-RLS agreement is that it is for compounds related to inflammation, spasticity, pain, and nervous system disorders. - Andrea Leone-Bay Chief Scientific Officer at Receptor Life Sciences
-IC 005. US 006 018 044 046 051 052. G & S: pharmaceutical preparations for human use; inhalers sold pre-filled with pharmaceutical preparations; plant extracts for pharmaceutical purposes
IC 042. US 100 101. G & S: scientific and medical research relating to the diagnosis and treatment of medical conditions; scientific and medical research relating to plant extracts for pharmaceutical purposes
IC 044. US 100 101. G & S: providing a website featuring information relating to the diagnosis and treatment of medical conditions
Read more: mnkd.proboards.com/thread/4988/receptor-life-science?page=22#ixzz44bMtTnWK
www.receptorlife.com/
" We can confirm that the company is funded by an important investor group, supported
by prominent business leaders in the Seattle area"
-Thank you for your interest in Receptor Life Sciences. We are pleased to be partnering with MannKind to deliver inhaled therapeutics utilizing their innovative platform. Our work is proceeding rapidly and we will look forward to sharing more exciting news with you as our activities become public.
Thank you again,
The Receptor Team
added: my words, in this dog eat dog world, this seems like a business opportunity whose time has come.
|
|
|
|
Post by cathode on Apr 1, 2016 16:04:00 GMT -5
My take: from the thread; - MNKD-RLS agreement is that it is for compounds related to inflammation, spasticity, pain, and nervous system disorders. - Andrea Leone-Bay Chief Scientific Officer at Receptor Life Sciences
-IC 005. US 006 018 044 046 051 052. G & S: pharmaceutical preparations for human use; inhalers sold pre-filled with pharmaceutical preparations; plant extracts for pharmaceutical purposes
IC 042. US 100 101. G & S: scientific and medical research relating to the diagnosis and treatment of medical conditions; scientific and medical research relating to plant extracts for pharmaceutical purposes
IC 044. US 100 101. G & S: providing a website featuring information relating to the diagnosis and treatment of medical conditions
Read more: mnkd.proboards.com/thread/4988/receptor-life-science?page=22#ixzz44bMtTnWK
www.receptorlife.com/
" We can confirm that the company is funded by an important investor group, supported
by prominent business leaders in the Seattle area"
-Thank you for your interest in Receptor Life Sciences. We are pleased to be partnering with MannKind to deliver inhaled therapeutics utilizing their innovative platform. Our work is proceeding rapidly and we will look forward to sharing more exciting news with you as our activities become public.
Thank you again,
The Receptor Team
added: my words, in this dog eat dog world, this seems like a business opportunity whose time has come.
You have pretty-well summed up what we know, from a pure fact point of view. Additional information is that the current set of executives are all lawyers from Lane Powell, a 125+ year old law firm based in Seattle and elsewhere. Matt had said that the name "Receptor Life Sciences" is new, but the company has been around for a while. --- I don't consider myself much of a speculator, which is almost all that can be done at this point. I am way more interested in this from the detective point of view, whereby facts are gathered and a picture is painted to reveal the maximum extent of the public knowledge about the company. Matt had previously stated that Andrea Leone-Bay had been let go as part of the restructuring of MannKind around the time of Hakan's resignation. He said it speaks volumes about the quality of RLS that they were able to recruit such a world-class expert such as Dr. Leone-Bay. It is the most logical case that she was hired because of her expertise in formulating drugs around the Technosphere delivery system. I seem to recall Matt saying that the TS platform was just one of the potential pathways RLS was exploring, though I cannot be certain that this memory is real. As for the Seattle backers, there is no real information on who they are. It is definitely an investor group, not a single individual. They are working through Lane Powell to set up the enterprise. I think the most revealing information so far comes from the details in the trademark, which you post. RLS wants to manufacture pre-filled inhalers (~Crickets) that are preloaded with proprietary plant extracts. ("proprietary" taken from the MannKind FAQ on the RLS agreement). They seem to be covering their bases with regard to not only delivering the extract, but researching the diagnosis and treatment of the specific conditions. This sounds like they are coming at the existing problems from a new standpoint. RLS has a pharmaceutical portfolio, and not just a single product. MannKind is on track to earn the first milestone this year, which is for an unknown amount. --- I am dismissive of any rumors or theories that directly contradict any of these facts. That is why I disregarded the TerSera idea. In the press release they mention that the company was formed in Feb 2016. I found the connection to Fiorentino's previous endeavor, Crealta Pharmaceuticals, far more in line with what we know about RLS' areas of interest -- CNS and arthritis. They were recently sold to Horizon Pharmaceuticals, though. If we are speculating within the known facts, then the idea that RLS is working on commercializing a cannabis extract seems to fit the bill as much as anything. CBD can aid in all of the ailments we know RLS is interested in -- chronic pain, spasticity, inflammation. CBD is an antogonist to receptor agonists. TS is valuable to RLS because it allows for the "immediate delivery of a consistent and precise dosage of the prescribed amount of an active therapeutic compound, while reducing unwanted side effects." (MNKD-RLS FAQ) Though not unique by any means, this certainly fits within the existing problems known with medical marijuana; the challenge of consistent and accurate dosages; limiting psychotropic effects due to THC. Medical marijuana use and research is legal within Washington State. My end take-away is that we (MNKD) have an agreement with a frankly mysterious company that highly values it's secrecy. We have the ability to make some cash up front this year, but as Matt said the real money comes from the royalties. Our former director of pharma discovery is now the chief scientific officer at this company. When RLS wants to be known, they will be. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 1, 2016 16:32:35 GMT -5
I think its Apple :-)
I believe its Apple. :-)
It is Apple.
|
|
|
|
Post by nylefty on Apr 1, 2016 17:04:45 GMT -5
I think its Apple :-) I believe its Apple. :-) It is Apple. I assume that you're making a (bad) joke. |
|
